Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 15/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285933 | 0.80 | NPC1 (0.45) | LCKMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2291165 | 0.75 | MAPT (0.41) | LCKMAPTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2289469 | 0.68 | MAPT (0.44) | MAPTRAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL18971579 | 0.68 | CHRNA7 (0.47) | LCKRAB9AMEN1NPC1KMT2A | |
| SCHEMBL1967266 | 0.68 | GAA (0.51) | LCKMAPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL13031486 | 0.68 | TP53 (0.70) | MAPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL1967649 | 0.68 | GAA (0.51) | LCKMAPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL26246644 | 0.67 | GAA (0.47) | MAPTRAB9AMEN1NPC1KMT2A | |
| SCHEMBL1970735 | 0.66 | GAA (0.52) | LCKMAPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL13031562 | 0.66 | TP53 (0.67) | LCKMAPTKMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | LCK 1479/4885MAPT 1138/4885RAB9A 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.